124 related articles for article (PubMed ID: 15199413)
21. [Stable interference on P210(bcr/abl) gene expression by lentiviral vector-delivered shRNA in vitro and in vivo].
Zhu YF; Wang YZ; Meng FY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1090-4. PubMed ID: 23114125
[TBL] [Abstract][Full Text] [Related]
22. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor.
Tomasson MH; Williams IR; Hasserjian R; Udomsakdi C; McGrath SM; Schwaller J; Druker B; Gilliland DG
Blood; 1999 Mar; 93(5):1707-14. PubMed ID: 10029600
[TBL] [Abstract][Full Text] [Related]
23. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
[TBL] [Abstract][Full Text] [Related]
24. Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants.
Corradini F; Cesi V; Bartella V; Pani E; Bussolari R; Candini O; Calabretta B
J Biol Chem; 2005 Aug; 280(34):30254-62. PubMed ID: 15927960
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
26. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
27. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV
Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018
[TBL] [Abstract][Full Text] [Related]
28. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.
Mayerhofer M; Aichberger KJ; Florian S; Krauth MT; Hauswirth AW; Derdak S; Sperr WR; Esterbauer H; Wagner O; Marosi C; Pickl WF; Deininger M; Weisberg E; Druker BJ; Griffin JD; Sillaber C; Valent P
FASEB J; 2005 Jun; 19(8):960-2. PubMed ID: 15784722
[TBL] [Abstract][Full Text] [Related]
29. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
Tipping AJ; Baluch S; Barnes DJ; Veach DR; Clarkson BM; Bornmann WG; Mahon FX; Goldman JM; Melo JV
Leukemia; 2004 Aug; 18(8):1352-6. PubMed ID: 15201856
[TBL] [Abstract][Full Text] [Related]
31. Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer.
Masiello D; Mohi MG; McKnight NC; Smith B; Neel BG; Balk SP; Bubley GJ
Cancer Biol Ther; 2007 Feb; 6(2):195-201. PubMed ID: 17218776
[TBL] [Abstract][Full Text] [Related]
32. TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin.
Majsterek I; Slupianek A; Blasiak J
Anticancer Drugs; 2003 Sep; 14(8):625-31. PubMed ID: 14501384
[TBL] [Abstract][Full Text] [Related]
33. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL.
Beissert T; Hundertmark A; Kaburova V; Travaglini L; Mian AA; Nervi C; Ruthardt M
Int J Cancer; 2008 Jun; 122(12):2744-52. PubMed ID: 18366061
[TBL] [Abstract][Full Text] [Related]
34. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
35. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
36. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
Oh B; Kim TY; Min HJ; Kim M; Kang MS; Huh JY; Kim Y; Lee DS
Anticancer Drugs; 2013 Jan; 24(1):20-31. PubMed ID: 23075630
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
38. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Griswold IJ; MacPartlin M; Bumm T; Goss VL; O'Hare T; Lee KA; Corbin AS; Stoffregen EP; Smith C; Johnson K; Moseson EM; Wood LJ; Polakiewicz RD; Druker BJ; Deininger MW
Mol Cell Biol; 2006 Aug; 26(16):6082-93. PubMed ID: 16880519
[TBL] [Abstract][Full Text] [Related]
39. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.
Miething C; Feihl S; Mugler C; Grundler R; von Bubnoff N; Lordick F; Peschel C; Duyster J
Leukemia; 2006 Apr; 20(4):650-7. PubMed ID: 16482207
[TBL] [Abstract][Full Text] [Related]
40. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene.
Magnusson MK; Meade KE; Nakamura R; Barrett J; Dunbar CE
Blood; 2002 Aug; 100(3):1088-91. PubMed ID: 12130532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]